[Peri-operative anticoagulation with danaparoid for a patient with Budd-Chiari syndrome and heparin-induced thrombocytopenia]

Ann Fr Anesth Reanim. 2004 Feb;23(1):50-5. doi: 10.1016/j.annfar.2003.10.009.
[Article in French]

Abstract

We report a case of Budd-Chiari syndrome revealing a polycythemia vera and complicated by heparin-induced thrombocytopenia. A surgical porto-caval shunt was inserted with danaparoid as anticoagulant during the peri-operative period. The doses of danaparoid were as follows: a continuous intravenous infusion of 200 U/h with a target between 0.5 et 0.8 U/ml antifactor Xa activity during the preoperative period, followed by 100 U/h with a target of 0.3 U/ml during the peroperative period; an increase in doses of danaparoid to 150 and 200 U/h with a target above 0.5 U/ml was used during the postoperative period. This case report is a rare situation of hypercoagulable state, in a surgical context, treated with danaparoid.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anticoagulants / adverse effects*
  • Anticoagulants / therapeutic use*
  • Budd-Chiari Syndrome / blood*
  • Chondroitin Sulfates / therapeutic use*
  • Dermatan Sulfate / therapeutic use*
  • Drug Combinations
  • Factor Xa Inhibitors
  • Female
  • Heparin / adverse effects*
  • Heparitin Sulfate / therapeutic use*
  • Humans
  • Infusions, Intravenous
  • Platelet Aggregation / drug effects
  • Thrombocytopenia / chemically induced*
  • Thrombocytopenia / drug therapy*

Substances

  • Anticoagulants
  • Drug Combinations
  • Factor Xa Inhibitors
  • Dermatan Sulfate
  • Heparin
  • Chondroitin Sulfates
  • Heparitin Sulfate
  • danaparoid